Striving to improve
We are working to advance a deep pipeline of precision therapies, designed to allow patients to live longer, healthier lives. Our approach combines our leading expertise in protein kinases with sound execution and an intense focus on discovery.
In addition to a diverse and growing portfolio of research programs, we are moving multiple investigational medicines through clinical development for patients with a broad range of genomically defined cancers and rare diseases.
Leveraging proven cancer drug targets
Thinking in giant leaps
A uniquely targeted, scalable approach
“Patients need treatments that can provide meaningful, lasting benefit. By targeting genomic drivers of disease, we believe we can get the right drugs to the right patients.”Andy Boral, M.D., Ph.D., Chief Medical Officer